Related Experiment Video
Updated: May 29, 2026
12:58
Characterizing Individual Protein Aggregates by Infrared Nanospectroscopy and Atomic Force Microscopy
Published on: September 12, 2019
Optical trapping for the characterization of amyloid-beta aggregation kinetics
Anthony J Veloso1, Hiroyuki Yoshikawa, Xin R Cheng
1Dept. of Physical and Environmental Sciences, University of Toronto at Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada.
The Analyst
|August 30, 2011
Summary
Researchers used near-infrared optical trapping and Congo Red dye to study early amyloid-beta (Aβ) aggregation in Alzheimer's disease (AD). This novel method offers new insights into the initial stages of Aβ plaque formation.
Area of Science:
- Biochemistry
- Neuroscience
- Biophysics
Background:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) plaque accumulation in neurons.
- Aβ oligomers are implicated in neuronal cell damage and disease progression.
- Understanding early Aβ aggregation is crucial for developing effective AD therapies.
Purpose of the Study:
- To investigate the early aggregation stages of amyloid-beta (Aβ) peptides.
- To apply novel techniques for characterizing Aβ oligomerization.
- To explore the utility of near-infrared (NIR) optical trapping in studying Aβ aggregation.
Main Methods:
- Utilized near-infrared (NIR) optical trapping to monitor Aβ aggregation.
- Employed Congo Red (CR) dye as a fluorescent marker for β-sheet structures.
- Integrated fluorescence analysis with optical trapping for real-time characterization.
Main Results:
- Successfully characterized the initial two hours of Aβ aggregation.
- Demonstrated the capability of NIR optical trapping to observe early aggregation events.
- Provided quantitative data on the kinetics of Aβ oligomer formation.
Conclusions:
- NIR optical trapping combined with CR fluorescence offers a powerful new method to study early Aβ aggregation.
- This technique provides novel insights into the initial phase of amyloid plaque formation relevant to Alzheimer's disease.
- Further research can leverage this approach to develop and test therapeutic interventions targeting early Aβ aggregation.
